• PARP7 Inhibition Stabilizes STAT1/2 and Alleviates EAE Sever

  2026-07-23

  Xu et al. uncover that PARP7 suppresses type I interferon signaling by promoting autophagic degradation of STAT1/STAT2, and that pharmacological inhibition of PARP7 relieves experimental autoimmune encephalomyelitis (EAE) in mice. These findings reveal a molecular checkpoint in neuroinflammation and provide a mechanistic rationale for targeting PARP7 in multiple sclerosis research.

• Reliable cDNA Synthesis with HyperScript™ RT SuperMix for qP

  2026-07-23

  This article addresses real-world challenges in cell viability and gene expression workflows, demonstrating how HyperScript™ RT SuperMix for qPCR (SKU K1074) delivers reproducible, sensitive cDNA synthesis, even with low-concentration or structurally complex RNA. Benchmarked against common pitfalls, the kit’s engineered enzyme and primer system empower robust, quantitative results for biomedical researchers.

• Hypertension Drives Atrial Remodeling via ATM/CHK2/p53 Pathw

  2026-07-22

  This study reveals that persistent hypertension leads to atrial fibrillation by inducing DNA damage and activating the ATM/CHK2/p53 signaling pathway, resulting in atrial remodeling, autophagy, and inflammation. Targeting this pathway could offer new therapeutic strategies for atrial fibrillation associated with chronic hypertension.

• WP1066, JAK2/STAT3 Inhibitor: Advanced Workflows in Cancer &

  2026-07-22

  WP1066, a potent JAK2/STAT3 inhibitor from APExBIO, empowers researchers to precisely dissect oncogenic and regenerative signaling in both cancer and bone healing models. This guide delivers actionable protocol enhancements, innovative applications, and troubleshooting tips to maximize reproducibility and translational insights.

• 2-NBDG Glucose Uptake Assay Kit: Precision in Glucose Metabo

  2026-07-21

  The 2-NBDG Glucose Uptake Assay Kit enables sensitive, single-cell analysis of glucose transporter activity using a non-radioactive, fluorescent approach. Its robust controls and rapid workflow empower researchers to dissect metabolic reprogramming in cancer, diabetes, and therapy resistance models with confidence.

• Indomethacin in Inflammation Research: Protocols and Innovat

  2026-07-21

  Indomethacin's dual Cox inhibition and PPAR agonism make it indispensable for dissecting inflammation and lipid metabolism at the bench. This article details state-of-the-art protocols, troubleshooting insights, and the translational impact of reference discoveries for next-generation anti-inflammatory drug research.

• Repurposing Clinically Safe Drugs for Modulating DNA Repair

  2026-07-20

  This study systematically screens FDA-approved drugs to modulate DNA double-strand break (DSB) repair pathway choice after CRISPR editing in human iPSCs. The findings provide a resource for precision genome editing and synthetic lethality strategies, highlighting opportunities to fine-tune repair outcomes for advanced disease modeling and therapeutic development.

• Propidium Iodide in Immunological Assays: Beyond Viability S

  2026-07-20

  Explore the advanced roles of Propidium iodide as a DNA intercalating dye in immunological research, including its use in apoptosis detection and immune cell profiling. This article reveals new assay insights and protocol parameters, offering depth beyond standard applications.

• Tropisetron Hydrochloride: Precision Tools for Translational

  2026-07-19

  This thought-leadership article explores Tropisetron Hydrochloride’s dual role as a selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist. Blending mechanistic insight with strategic guidance, it empowers translational researchers to design rigorous, reproducible studies in neuroscience receptor modulation and serotonin pathway signaling. The discussion integrates recent evidence on transporter inhibition, competitive compounds, and forward-thinking protocol guidance, while situating APExBIO’s high-purity solution as a cornerstone for cutting-edge research.

• Vasopressin Analogues: Therapeutic Roles and Research Advanc

  2026-07-18

  This review synthesizes key advances in the development and application of vasopressin analogues, with an emphasis on their therapeutic versatility, molecular modifications, and translational challenges. Notably, the paper highlights lypressin acetate as a clinically relevant peptide for diabetes insipidus and explores the expanding potential of vasopressin analogues—including antiviral research targeting SARS-CoV-2.

• Losmapimod (GW856553X): Precision Inflammation Signaling Mod

  2026-07-17

  Losmapimod (GW856553X) enables researchers to dissect and modulate p38 MAPK-driven inflammation and vascular responses with unprecedented specificity. By leveraging new mechanistic insights into dual-action kinase inhibition, investigators can enhance preclinical assay precision and accelerate translational research in cardiovascular and COPD models.

• Exo1: Precision Membrane Trafficking Inhibition for Exocytos

  2026-07-17

  Exo1 (methyl 2-(4-fluorobenzamido)benzoate) delivers acute, selective inhibition of Golgi-to-ER membrane trafficking, empowering researchers to dissect exocytic pathway dynamics with unparalleled specificity. Its unique mechanism—distinct from Brefeldin A—offers critical workflow advantages for studying ARF1-mediated processes and tumor extracellular vesicle (TEV) release.

• Fenipentol: Molecular Insights and Translational Advances in

  2026-07-16

  Explore Fenipentol (1-Phenyl-1-pentanol) as both a choleretic agent and a modulator of fibrotic signaling. This in-depth analysis uncovers molecular mechanisms, assay protocols, and translational research implications beyond routine gastrointestinal studies.

• NVP-BGJ398 Phosphate: Advanced FGFR Inhibition Workflows

  2026-07-16

  NVP-BGJ398 phosphate empowers researchers to dissect FGFR-driven disease mechanisms, spanning oncology and rare skeletal disorders. This guide translates recent in vivo breakthroughs into executable protocols and troubleshooting strategies for robust, reproducible results.

• Annexin-V Detection of Cardiomyocyte Death in Mouse I/R Mode

  2026-07-15

  The reference study introduces labeled recombinant human annexin-V as a robust tool for detecting early cardiomyocyte death in vivo following myocardial ischemia and reperfusion in mice. This approach enhances temporal mapping of cell death and enables rigorous evaluation of cell death–blocking strategies, with significant implications for preclinical cardiovascular research.

14817 records 1/988 page Next 12345 下5页 Last page